

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Current trends in the treatment of pneumonia due to... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-121/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-121" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria" />
    
            <meta name="og:title" content="F1000Research Article: Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria.">
            <meta name="og:description" content="Read the latest article version by Richard R. Watkins, David Van Duin, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="19889">
            <meta name="article-id" content="16517">
            <meta name="dc.title" content="Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria">
            <meta name="dc.description" content="Pneumonia is one of the most common infections worldwide. Morbidity, mortality, and healthcare costs increase substantially when pneumonia is caused by multidrug-resistant Gram-negative bacteria (MDR-GNB). The ongoing spread of antimicrobial resistance has made treating MDR-GNB pneumonia increasingly difficult. Fortunately, there have been some recent additions to our antibiotic armamentarium in the US and Europe for MDR-GNB, along with several agents that are in advanced stages of development. In this article, we review the risk factors for and current management of MDR-GNB pneumonia as well as novel agents with activity against these important and challenging pathogens.">
            <meta name="dc.subject" content="Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, antibiotics">
            <meta name="dc.creator" content="Watkins, Richard R.">
            <meta name="dc.creator" content="Van Duin, David">
            <meta name="dc.date" content="2019/02/06">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.16517.2">
            <meta name="dc.source" content="F1000Research 2019 8:121">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.relation" content="doi:10.12688/f1000research.16517.1">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Enterobacteriaceae">
            <meta name="prism.keyword" content="Pseudomonas aeruginosa">
            <meta name="prism.keyword" content="Acinetobacter baumannii">
            <meta name="prism.keyword" content="antibiotics">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/02/06">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="121">
            <meta name="prism.versionIdentifier" content="2">
            <meta name="prism.doi" content="10.12688/f1000research.16517.2">
            <meta name="prism.url" content="https://f1000research.com/articles/8-121">
            <meta name="citation_title" content="Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria">
            <meta name="citation_abstract" content="Pneumonia is one of the most common infections worldwide. Morbidity, mortality, and healthcare costs increase substantially when pneumonia is caused by multidrug-resistant Gram-negative bacteria (MDR-GNB). The ongoing spread of antimicrobial resistance has made treating MDR-GNB pneumonia increasingly difficult. Fortunately, there have been some recent additions to our antibiotic armamentarium in the US and Europe for MDR-GNB, along with several agents that are in advanced stages of development. In this article, we review the risk factors for and current management of MDR-GNB pneumonia as well as novel agents with activity against these important and challenging pathogens.">
            <meta name="citation_description" content="Pneumonia is one of the most common infections worldwide. Morbidity, mortality, and healthcare costs increase substantially when pneumonia is caused by multidrug-resistant Gram-negative bacteria (MDR-GNB). The ongoing spread of antimicrobial resistance has made treating MDR-GNB pneumonia increasingly difficult. Fortunately, there have been some recent additions to our antibiotic armamentarium in the US and Europe for MDR-GNB, along with several agents that are in advanced stages of development. In this article, we review the risk factors for and current management of MDR-GNB pneumonia as well as novel agents with activity against these important and challenging pathogens.">
            <meta name="citation_keywords" content="Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, antibiotics">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Richard R. Watkins">
            <meta name="citation_author_institution" content="Division of Infectious Diseases, Cleveland Clinic Akron General, Akron, OH, 44302, USA">
            <meta name="citation_author_institution" content="Department of Medicine, Northeast Ohio Medical University, Rootstown, OH, 44272, USA">
            <meta name="citation_author" content="David Van Duin">
            <meta name="citation_author_institution" content="Department of Medicine, University of North Carolina, Chapel Hill, NC, 27514, USA">
            <meta name="citation_publication_date" content="2019/02/06">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="121">
            <meta name="citation_version_number" content="2">
            <meta name="citation_doi" content="10.12688/f1000research.16517.2">
            <meta name="citation_firstpage" content="121">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-121/v2/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-121.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=19889 /> <input type=hidden id=articleId name=articleId value=16517 /> <input type=hidden id=xmlUrl value="/articles/8-121/v2/xml"/> <input type=hidden id=xmlFileName value="-8-121-v2.xml"> <input type=hidden id=article_uuid value=7b526853-586f-45ec-81eb-ffa3dcf7697c /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.16517.2"/> <input type=hidden id=versionDoi value="10.12688/f1000research.16517.2"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-121"
  },
  "headline": "Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria",
  "datePublished": "2019-01-30T12:31:34",
  "dateModified": "2019-02-06T11:36:49",
  "author": [
    {
      "@type": "Person",
      "name": "Richard R. Watkins"
    },    {
      "@type": "Person",
      "name": "David Van Duin"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Pneumonia is one of the most common infections worldwide. Morbidity, mortality, and healthcare costs increase substantially when pneumonia is caused by multidrug-resistant Gram-negative bacteria (MDR-GNB). The ongoing spread of antimicrobial resistance has made treating MDR-GNB pneumonia increasingly difficult. Fortunately, there have been some recent additions to our antibiotic armamentarium in the US and Europe for MDR-GNB, along with several agents that are in advanced stages of development. In this article, we review the risk factors for and current management of MDR-GNB pneumonia as well as novel agents with activity against these important and challenging pathogens."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-121",
            "name": "Current trends in the treatment of pneumonia due to multidrug-resistant..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Current trends in the treatment of pneumonia due to multidrug-resistant... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=19889 data-id=16517 data-downloads="" data-views="" data-scholar="10.12688/f1000research.16517.2" data-recommended="" data-doi="10.12688/f1000research.16517.2" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-121/v2/pdf?article_uuid=7b526853-586f-45ec-81eb-ffa3dcf7697c" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-16517-2> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-16517-2 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-16517-2 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Watkins RR and Van Duin D. Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria [version 2; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):121 (<a class=new-orange href="https://doi.org/10.12688/f1000research.16517.2" target=_blank>https://doi.org/10.12688/f1000research.16517.2</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-16517-2" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=16517 id=track-article-signin-16517 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/16517?target=/articles/8-121">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=19889 /> <input name=articleId type=hidden value=16517 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <span title="A revision, usually following reviewer/reader feedback" class=" updated-box updated-box-bg orange-bg revised helper">Revised</span> <h1>Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria</h1><span class=other-info> [version 2; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:WatkinR2@ccf.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Richard R. Watkins</span></a><sup>1,2</sup>,&nbsp;</span><span class="">David Van Duin<sup>3</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:WatkinR2@ccf.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Richard R. Watkins</span></a><sup>1,2</sup>,&nbsp;</span><span class="">David Van Duin<sup>3</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 06 Feb 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.16517.2"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Division of Infectious Diseases, Cleveland Clinic Akron General, Akron, OH, 44302, USA<br/> <sup>2</sup> Department of Medicine, Northeast Ohio Medical University, Rootstown, OH, 44272, USA<br/> <sup>3</sup> Department of Medicine, University of North Carolina, Chapel Hill, NC, 27514, USA<br/> <p> <div class=margin-bottom> Richard R. Watkins <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> David Van Duin <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=44948-43432></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=44949-43431></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Pneumonia is one of the most common infections worldwide. Morbidity, mortality, and healthcare costs increase substantially when pneumonia is caused by multidrug-resistant Gram-negative bacteria (MDR-GNB). The ongoing spread of antimicrobial resistance has made treating MDR-GNB pneumonia increasingly difficult. Fortunately, there have been some recent additions to our antibiotic armamentarium in the US and Europe for MDR-GNB, along with several agents that are in advanced stages of development. In this article, we review the risk factors for and current management of MDR-GNB pneumonia as well as novel agents with activity against these important and challenging pathogens. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, antibiotics </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Richard R. Watkins (<a href="mailto:WatkinR2@ccf.org">WatkinR2@ccf.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Richard R. Watkins </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> RRW serves on an advisory board and speakers’ bureau and has received research support from Allergan. DvD serves on advisory boards for Allergan, Achaogen, Shionogi, Tetraphase, Sanofi Pasteur, MedImmune, and Astellas and has received research funding from Steris Inc. and Scynexis. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Watkins RR and Van Duin D. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Watkins RR and Van Duin D. Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria [version 2; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):121 (<a href="https://doi.org/10.12688/f1000research.16517.2" target=_blank>https://doi.org/10.12688/f1000research.16517.2</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 30 Jan 2019, <b>8</b>(F1000 Faculty Rev):121 (<a href="https://doi.org/10.12688/f1000research.16517.1" target=_blank>https://doi.org/10.12688/f1000research.16517.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 06 Feb 2019, <b>8</b>(F1000 Faculty Rev):121 (<a href="https://doi.org/10.12688/f1000research.16517.2" target=_blank>https://doi.org/10.12688/f1000research.16517.2</a>)</span> </div> <div class="update-box-wrapper update-text-view-control article-updated-box "> <h2 class="h2-title no-top-margin"> <span title="A revision, usually following reviewer/reader feedback" class=" updated-box updated-box-bg orange-bg revised ">Revised</span> Amendments from Version 1 <span class="research-layout f1r-article-mobile-inline update-box-control"> <span class="f1r-icon icon-14_more_small big midgrey"></span> <span class="f1r-icon icon-10_less_small big midgrey" style="display: none;"></span> </span> </h2> <div class=f1r-article-desk> <p>This version corrects an error in version 1 that stated there is an oral formulation of eravacycline, which there is not.</p> </div> <div class="f1r-article-mobile research-layout article-page-general-text-mobile padding-top-20" style="display: none;"> This version corrects an error in version 1 that stated there is an oral formulation of eravacycline, which there is not. </div> <p class=f1r-article-desk> <b>To read any peer review reports and author responses for this article, follow the "read" links in the Open Peer Review table.</b> </p> <span class=f1r-article-mobile> <div class="margin-top-30 margin-bottom research-layout is-centered" style="display: none;"> <a href="#article-reports"> <button class="primary orange extra-padding">READ REVIEWER RESPONSES</button> </a> </div> </span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d6896e164>Introduction</h2><p class="" id=d6896e167>Infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB) pose a serious and increasing threat to human health. This is particularly true in the pathogenesis of pneumonia, where escalating rates of antimicrobial resistance (AMR) have been associated with excessive morbidity, mortality, and healthcare costs<sup><a href="#ref-1">1</a></sup>. It is well recognized that timely and effective therapy is vital for improving outcomes, especially for pneumonia that is hospital acquired<sup><a href="#ref-2">2</a></sup>. The choice of initial antibiotic therapy for pneumonia is based on several factors, including recommendations from guidelines, national and local antimicrobial susceptibility data, and patient characteristics such as allergies and renal function. For many years, the backbone of treatment for pneumonia has been the β-lactam class of antibiotics, including the third- and fourth-generation cephalosporins and β-lactam/β-lactamase inhibitor combinations like piperacillin/tazobactam<sup><a href="#ref-3">3</a></sup>. Unfortunately, the ongoing spread of extended-spectrum β-lactamases (ESBLs) and carbapenemases such as <i>Klebsiella pneumonia</i> carbapenemase (KPC) has begun to limit the clinical effectiveness of β-lactam agents over the last decade<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup>.</p><p class="" id=d6896e192>The diagnosis of pneumonia can be challenging, especially in cases of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Indeed, pulmonary infiltrates on imaging in critically ill patients are common and can be due to non-infectious etiologies, including atelectasis, acute respiratory distress syndrome (ARDS), congestive heart failure (CHF), pulmonary hemorrhages, and pulmonary infarction. Moreover, upper airways and endotracheal tubes of hospitalized patients are often colonized by MDR-GNB and their presence does not necessarily mean that they are the cause of the pulmonary abnormalities seen on imaging studies. A careful clinical assessment is therefore imperative when evaluating for pneumonia, especially in patients who have had a prolonged hospitalization. The current HAP/VAP guidelines from the Infectious Diseases Society of America are an excellent reference for help with diagnosing these cases<sup><a href="#ref-2">2</a></sup>.</p><p class="" id=d6896e199>The initial approach to pneumonia is most often empirical because results of antimicrobial susceptibility testing typically take 48 to 72 hours. Rapid diagnostic tests (RDTs), including molecular methods that identify specific resistance genes or automated microscopy that can quickly determine antibiotic susceptibility, have great potential for guiding empiric antibiotic therapy. But current RDTs have limitations and most have not been validated for respiratory secretions<sup><a href="#ref-6">6</a></sup>. Deciding on an appropriate empirical regimen can be difficult because clinicians must consider the benefits of starting therapy early versus the harms of unnecessary coverage. Indeed, inappropriate antimicrobial treatment or delays in starting appropriate treatment in VAP are associated with increased morbidity and mortality<sup><a href="#ref-7">7</a></sup>. Once susceptibility testing results are available, empiric antibiotic therapy should be de-escalated. Most cases of MDR-GNB pneumonia can be successfully treated with 7 days of therapy<sup><a href="#ref-2">2</a></sup>.</p><p class="" id=d6896e214>Several risk factors for MDR-GNB pneumonia have been identified. These include prior infection or colonization with MDR-GNB, antibiotic therapy in the past 90 days, poor functional status performance, hospitalization for more than 2 days in the past 90 days, occurrence 5 or more days after admission to an acute hospital, receiving hemodialysis, and immunosuppression<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>. Moreover, prior receipt of carbapenems, broad-spectrum cephalosporins, and fluoroquinolones has been associated specifically with MDR <i>Pseudomonas aeruginosa</i><sup><a href="#ref-10">10</a></sup>.</p><p class="" id=d6896e231>Recently, the high mortality and mortality associated with MDR-GNB pneumonia along with limited treatment options have led to a resurgence in the use of the nephrotoxic drug colistin<sup><a href="#ref-11">11</a></sup>. Fortunately, several new antibiotic agents with activity against MDR-GNB, including plazomicin, ceftazidime/avibactam, and meropenem/vaborbactam, have become available. This review discusses new antibiotic options for MDR-GNB and those in late stages of clinical development and provides guidance for their use in treating MDR-GNB pneumonia.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6896e241>Multidrug-resistant Enterobacteriaceae</h2><p class="" id=d6896e244>Similar to other MDR-GNB, MDR Enterobacteriaceae are usually encountered as the cause of healthcare-associated pneumonia and are less commonly seen in community-acquired pneumonia (CAP). In a recent large intensive care unit (ICU) study of 75 US centers, the most common Enterobacteriaceae isolated from patients with pneumonia were <i>Klebsiella pneumoniae</i>, <i>Enterobacter</i> spp., and <i>Escherichia coli</i>, which accounted for 12%, 8%, and 7% of all bacterial isolates included in the study, respectively<sup><a href="#ref-12">12</a></sup>. Important MDR Enterobacteriaceae that cause pneumonia include those bacteria that produce AmpC enzymes, ESBL, or carbapenemases or a combination of these. AmpC and ESBL producers are usually resistant to most, if not all, cephalosporins. ESBL but not AmpC producers are variably inhibited by β-lactamase inhibitors. Also, AmpC enzymes are frequently found in <i>Enterobacter</i> spp. and may be induced by antibiotic treatment, leading to treatment-emergent resistance<sup><a href="#ref-13">13</a></sup>. As AmpC enzymes do not effectively hydrolyze cefepime, AmpC-producing Enterobacteriaceae often retain <i>in vitro</i> susceptibility to cefepime<sup><a href="#ref-13">13</a></sup>. The management of pneumonia caused by carbapenem-resistant Enterobacteriaceae (CRE) is the most challenging. In a longitudinal cohort study of patients with CRE, pneumonia and bloodstream infections (BSIs) were found to be associated with the highest mortality rates<sup><a href="#ref-14">14</a></sup>. When compared with comparable patients colonized with CRE, CRE pneumonia had an excess hospital mortality of 27% and adjusted hazard ratio of 3.44 (95% confidence interval [CI] 1.80–6.48, <i>p</i>&lt;0.001) for time to death<sup><a href="#ref-14">14</a></sup>. Risk factors for MDR Enterobacteriaceae as a cause of pneumonia overlap with those of other MDR organisms and include prior exposure to antibiotics, healthcare exposure, and use of medical devices such as urinary catheters<sup><a href="#ref-15">15</a>,<a href="#ref-16">16</a></sup>.</p><p class="" id=d6896e294>An excellent comprehensive review on the therapy of MDR Enterobacteriaceae was recently published by Rodríguez-Baño <i>et al</i>. and the reader is referred to this review for additional background<sup><a href="#ref-17">17</a></sup>. It is important to note that the MERINO trial (Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible <i>Escherichia coli</i> and <i>Klebsiella</i> spp.) had not yet been published at the time of that review. In the MERINO trial, patients with BSI caused by ceftriaxone-resistant Enterobacteriaceae were randomly assigned to receive either piperacillin/tazobactam or meropenem in an open-label non-inferiority design<sup><a href="#ref-18">18</a></sup>. The mechanism of resistance in these isolates was an ESBL in about 85% and AmpC in about 10%. In contrast to some observational studies, the mortality in piperacillin/tazobactam-treated patients was significantly higher as compared with those treated with meropenem (12% versus 4%)<sup><a href="#ref-18">18</a>,<a href="#ref-19">19</a></sup>. A total of 12 out of 379 patients had pneumonia as a source of BSI in this study. Similarly, in a randomized controlled trial comparing cefepime versus imipenem in the treatment of pneumonia, a decreased efficacy of cefepime was noted in patients infected with ESBL-producing Enterobacteriaceae<sup><a href="#ref-20">20</a></sup>. Based on these data, carbapenems should be considered first-line treatment for pneumonia caused by ESBL-producing Enterobacteriaceae. In an observational study of AmpC-producing Enterobacteriaceae BSI, patients who received definitive therapy with piperacillin/tazobactam were compared with a group of patients who received either cefepime or piperacillin/tazobactam. Only 14% and 20% of patients had pneumonia as the source of BSI<sup><a href="#ref-21">21</a></sup>. Although no statistically significant differences were found, it was notable that the 30-day mortality in the piperacillin/tazobactam-treated patients was 15% versus 7% in the meropenem- or cefepime-treated patients<sup><a href="#ref-21">21</a></sup>. Based on these clinical data and the known hydrolysis of piperacillin by AmpC, piperacillin/tazobactam cannot be considered first-line treatment for AmpC-producing Enterobacteriaceae. As mechanisms of resistance are usually not available to treating clinicians, practically speaking, piperacillin/tazobactam should not be used for pneumonia caused by <i>Enterobacter</i> spp., <i>Serratia</i> spp., or <i>Citrobacter</i> spp.</p><p class="" id=d6896e344>Whether cefepime can be successfully used in the treatment of pneumonia caused by AmpC-producing Enterobacteriaceae remains unclear. In a propensity-adjusted analysis of observational data on patients with infections caused by AmpC-producing Enterobacteriaceae, treatment with cefepime (n = 32) was compared with meropenem (n = 32)<sup><a href="#ref-22">22</a></sup>. Pneumonia was present in 53% and 41% of cefepime- and meropenem-treated patients, respectively. Overall, no difference in 30-day mortality was seen (odds ratio [OR] 0.63, 95% CI 0.23–211), but it should be noted that this OR had a wide CI that included both a fourfold decreased odds of 30-day mortality in cefepime-treated patients and a twofold increased odds<sup><a href="#ref-22">22</a></sup>. Given the absence of activity of AmpC against cefepime and these limited clinical results, cefepime is a reasonable carbapenem-sparing option for pneumonia caused by AmpC-positive Enterobacteriaceae.</p><p class="" id=d6896e355>Carbapenem resistance in Enterobacteriaceae can be mediated through carbapenemases, which are usually carried on mobile genetic elements such as plasmids (carbapenemase-producing Enterobacteriaceae, or CPE), or through a variety of other mechanisms such as porin mutations (non-carbapenemase-producing CRE). Important classes of carbapenemases include KPC, New Delhi metallo-β-lactamases (NDMs), and OXA-48-like carbapenemases<sup><a href="#ref-23">23</a></sup>. Prior to the availability of newer antibiotics, treatment of invasive CRE infections included the use of polymyxins, tigecycline, and aminoglycosides, often given in combination regimens<sup><a href="#ref-24">24</a></sup>. More recently, meropenem/vaborbactam, ceftazidime/avibactam, eravacycline, and plazomicin have become available<sup><a href="#ref-25">25</a>–<a href="#ref-27">27</a></sup>. These agents have specific <i>in vitro</i> anti-CRE activity. Plazomicin has broad activity regardless of carbapenemase but is inactivated by 16S rRNA ribosomal methyltransferases that are present in some NDM-producing CPE<sup><a href="#ref-28">28</a></sup>. Meropenem/vaborbactam is active against KPC-producing CPE, and avibactam inhibits KPC and OXA-48-like carbapenemases<sup><a href="#ref-25">25</a>,<a href="#ref-29">29</a></sup>. Eravacycline is a fluorocycline antibiotic similar in structure to tigecycline with activity against CRE<sup><a href="#ref-30">30</a></sup>. In addition, there are several other anti-CRE agents in the pipeline, including cefiderocol, imipenem/relebactam, and meropenem/nacubactam.</p><p class="" id=d6896e393>With the availability of these new agents, there are some (but no definitive) clinical data available on the best treatment of CRE infections, including CRE pneumonia. In an observational study, patients with CRE infections—caused primarily by KPC producers—who were started on colistin (n = 99) were compared with patients who were started on ceftazidime/avibactam (n = 38)<sup><a href="#ref-31">31</a></sup>. In an inverse probability of treatment-weighted analysis, the 30-day mortality in patients on colistin was 32% versus 9% (absolute difference 23%, 95% CI 9%–35%; <i>p</i> = 0.001) in those on ceftazidime/avibactam. Pneumonia was present in 24% and 32% of patients on colistin and ceftazidime/avibactam, respectively<sup><a href="#ref-31">31</a></sup>. In a randomized controlled trial, plazomicin was compared with colistin—both given in combination with either tigecycline or meropenem—in CRE BSI (n = 29) or pneumonia (n = 8)<sup><a href="#ref-32">32</a></sup>. Plazomicin versus colistin therapy was associated with 2/17 (12%) versus 8/20 (40%) all-cause mortality at day 28<sup><a href="#ref-32">32</a></sup>. Similarly, meropenem/vaborbactam (n = 28) was compared with best available therapy (n = 15) for CRE infections, 5 of which were pneumonia<sup><a href="#ref-26">26</a></sup>. Rates of clinical cure at test of cure visit were 57% and 27% in the meropenem-vaborbactam and best available therapy arms, respectively<sup><a href="#ref-26">26</a></sup>. Based on these data, it is clear that polymyxin-based therapy is inferior to treatment with one of these novel agents. Although only limited numbers of patients with CRE pneumonia were studied, the use of either meropenem-vaborbactam or ceftazidime-avibactam in CRE pneumonia is a reasonable approach while awaiting more data. Ceftazidime/avibactam was shown to be non-inferior to meropenem in a recent large randomized controlled trial of non-CRE pneumonia<sup><a href="#ref-33">33</a></sup>. Meropenem itself has been used as a comparator agent in many pneumonia studies, and vaborbactam achieves high epithelial lining fluid concentrations<sup><a href="#ref-34">34</a></sup>. In contrast, in the absence of confirmatory data, plazomicin should not be considered a first-line choice for monotherapy of CRE pneumonia.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6896e435><i>Pseudomonas aeruginosa</i>&nbsp;</h2><p class="" id=d6896e440>The acquisition of MDR <i>P. aeruginosa</i>, a significant and increasing cause of HAP/VAP in North America and Europe, is related to both patient factors (for example, older age, previous colonization, recent broad-spectrum antibiotic use, malignancy, and presence of shock) and nosocomial factors (for example, admission to a ward with a high incidence of MDR strains)<sup><a href="#ref-35">35</a></sup>. Indeed, recent receipt of an anti<b>-</b>pseudomonal antibiotic, especially quinolones and carbapenems, appears to be an important driver of MDR <i>P. aeruginosa</i> acquisition<sup><a href="#ref-10">10</a></sup>. Compared with less-resistant strains, pneumonia due to MDR <i>P. aeruginosa</i> is associated with longer stays in the ICU, prolonged mechanical ventilation, and greater mortality<sup><a href="#ref-36">36</a></sup>. Thus, improving the management of MDR <i>P. aeruginosa</i> pneumonia must be a priority in order to improve outcomes from both clinical and financial standpoints.</p><p class="" id=d6896e471>At present, there is no high-grade evidence to guide management decisions for MDR <i>P. aeruginosa</i> pneumonia. Current guidelines recommend combination empiric therapy when AMR is a concern and suggest that aminoglycosides and colistin be avoided if alternative agents are available (low-quality evidence)<sup><a href="#ref-2">2</a></sup>. An anti-pseudomonal cephalosporin, carbapenem, fluoroquinolone, or β-lactam/β-lactamase inhibitor is a potential option for initial therapy. Once susceptibility results are available, combination therapy can be de-escalated to monotherapy in most cases. However, combination therapy should be continued for patients in septic shock or at a high risk for death<sup><a href="#ref-2">2</a></sup>. Patients with VAP due to MDR <i>P. aeruginosa</i> that is susceptible to only aminoglycosides or polymyxins should receive both inhaled and systemic antibiotics rather than systemic antibiotics alone<sup><a href="#ref-2">2</a></sup>. In addition to adequate antibiotic coverage, other factors such as adequate drug dosing, appropriate intervals of drug administration, and duration of therapy (usually 7 days) are important for achieving optimal clinical outcomes. For example, a single-center retrospective study found that mortality was significantly lower in patients with <i>P. aeruginosa</i> pneumonia who received extended-infusion cefepime versus standard dosing (20% versus 3%, respectively; <i>p</i> = 0.03), along with significantly lower length of ICU stay (18.5 versus 8 days, respectively; <i>p</i> = 0.04)<sup><a href="#ref-37">37</a></sup>.</p><p class="" id=d6896e506>Several new antibiotics with activity against MDR <i>P. aeruginosa</i> have become available recently or are in late stages of development. Ceftolozane/tazobactam is a combination of a novel cephalosporin with a modified side chain and a β-lactamase inhibitor. The potent anti-pseudomonal activity of ceftolozane/tazobactam is attributed to its ability to evade the resistance mechanisms of <i>P</i>. <i>aeruginosa</i>, including efflux pumps, reduced uptake through porins, and modification of penicillin-binding proteins (PBPs)<sup><a href="#ref-38">38</a></sup>. A higher dose (3 g intravenously [IV] every 8 hours) has been recommended for treating pneumonia compared with the currently approved dose (1.5 g IV every 8 hours) based on pharmacokinetic estimates for achieving a more than 90% probability of target attainment for the 1-log kill target against pathogens with a minimum inhibitory concentration (MIC) of not more than 8 mg/L in epithelial lining fluid<sup><a href="#ref-39">39</a></sup>. Of concern is a recent retrospective study from a single center in Germany that reported that 55% of <i>P. aeruginosa</i> isolates were resistant to ceftolozane/tazobactam, which the authors suggested may be due to carriage of the VIM-2 carbapenemase<sup><a href="#ref-40">40</a></sup>. Notably, ceftolozane/tazobactam lacks activity against Ambler class B (metallo-)carbapenemases, such as VIM and NDM.</p><p class="" id=d6896e534>Ceftazidime/avibactam, a combination of a third-generation cephalosporin and a novel synthetic non-β-lactam, β-lactamase inhibitor, is also ineffective against metallo-β-lactamases. In pooled data from five randomized controlled trials including one on HAP/VAP (REPROVE), 95 cases of MDR <i>P. aeruginosa</i> were identified<sup><a href="#ref-41">41</a></sup>. The favorable microbiological response rates at test of cure for MDR <i>P. aeruginosa</i> were 57.1% for ceftazidime/avibactam and 53.8% for comparators, primarily carbapenems<sup><a href="#ref-41">41</a></sup>. Thus, ceftazidime/avibactam likely has a role as a carbapenem-sparing agent for treating MDR <i>P. aeruginosa</i> pneumonia. Recent data suggest that ceftazidime/avibactam is a viable option against strains of MDR <i>P. aeruginosa</i> that are resistant to ceftolozane/tazobactam<sup><a href="#ref-42">42</a></sup>.</p><p class="" id=d6896e563>Cefiderocol is a novel siderophore cephalosporin that inhibits cell wall synthesis through the formation of an iron ion complex that penetrates bacteria via a ferric iron transporter system<sup><a href="#ref-43">43</a></sup>. Cefiderocol has demonstrated potent activity against β-lactamase-producing <i>P. aeruginosa</i>, including those expressing ESBLs, Ambler class A β-lactamases, and metallo-β-lactamases<sup><a href="#ref-44">44</a>,<a href="#ref-45">45</a></sup>. Currently, there is a randomized clinical trial under way for the treatment of HAP comparing the combination of cefiderocol and linezolid with linezolid and meropenem (ClinicalTrials.gov Identifier: NCT03032380)<sup><a href="#ref-46">46</a></sup>. The novel β-lactamase inhibitor relebactam inhibits Ambler class A and C β-lactamases and is in development in combination with imipenem. According to data from a global surveillance program that included Africa, Asia, Europe, Latin America, the Middle East, US/Canada, and the South Pacific, imipenem/relebactam inhibited 90.8% of all <i>P. aeruginosa</i> isolates and 70.7% of MDR <i>P. aeruginosa</i> isolates (n = 3,708)<sup><a href="#ref-47">47</a></sup>. A study on patients with HAP/VAP is ongoing. Finally, though still in early development, murepavadin is the first member of a novel class of outer membrane protein-targeting antibiotics specifically designed to target <i>P. aeruginosa</i><sup><a href="#ref-48">48</a></sup>. In a study that included 785 isolates of extremely drug-resistant <i>P. aeruginosa</i>, Sader <i>et al</i>. reported that murepavadin showed potent activity against isolates that were non-susceptible to colistin, ceftolozane/tazobactam, or tobramycin or a combination of these<sup><a href="#ref-49">49</a></sup>. These promising findings raise hopes for the further development of murepavadin.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6896e615><i>Acinetobacter baumannii</i>&nbsp;</h2><p class="" id=d6896e620>Most cases of <i>Acinetobacter baumannii</i> pneumonia occur in hospitalized patients, although it is occasionally seen in CAP<sup><a href="#ref-50">50</a></sup>. Therefore, the recent report that, after increasing for many years, the rate of AMR in <i>A. baumannii</i> hospital-acquired infections may be leveling off is grounds for cautious optimism<sup><a href="#ref-51">51</a></sup>. AMR in <i>A. baumannii</i> is the primary reason that clinicians prescribe ineffective empirical antibiotic therapy, often leading to poor outcomes<sup><a href="#ref-52">52</a></sup>. For example, VAP due to MDR <i>A. baumannii</i> results in significantly lower rates of successful ventilator weaning compared with susceptible strains<sup><a href="#ref-53">53</a></sup>. A retrospective cohort study that included 175 hospitals found that having pneumonia or sepsis from MDR <i>A. baumannii</i> was significantly associated with receiving inappropriate antibiotic therapy and higher hospital mortality<sup><a href="#ref-54">54</a></sup>. Thus, it is crucial that risk factors for MDR <i>A. baumannii</i> be recognized early so that appropriate empiric therapy can be rapidly initiated.</p><p class="" id=d6896e662>When pneumonia due to MDR <i>A. baumannii</i> is suspected (that is, during an <i>A. baumannii</i> outbreak, in an endemic setting, or in a previously colonized patient), combination therapy including a polymyxin should be empirically prescribed until susceptibilities are known<sup><a href="#ref-55">55</a></sup>. If clinical suspicion for resistance is low, then a carbapenem (except ertapenem, which lacks activity against <i>A. baumannii</i>) should be first-line therapy. Many combination therapies for MDR <i>A. baumannii</i> have been investigated and were recently discussed by Vazquez Guillamet and Kollef<sup><a href="#ref-6">6</a></sup>. Polymyxins remain the backbone of combination regimens. A retrospective cohort study that included patients with pneumonia caused by strains of <i>A. baumannii</i> susceptible only to colistin and tigecycline compared three combination regimens: colistin and high-dose sulbactam (n = 93), colistin and tigecycline (n = 43), and colistin and high-dose prolonged infusion of a carbapenem (n = 30)<sup><a href="#ref-56">56</a></sup>. The 28-day survival rate and mean length of hospital stay were not statistically different between regimens, whereas an elevated Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) score, delay in receipt of an active regimen, underlying malignancy, and chronic kidney disease were all significantly associated with increased mortality<sup><a href="#ref-56">56</a></sup>. Using a loading dose of IV colistin for MDR <i>A. baumannii</i> VAP appears to have no significant effect on clinical cure rates or bacteriologic clearance but does increase the risk for nephrotoxicity<sup><a href="#ref-57">57</a></sup>. The addition of inhaled colistin to systemic therapies has generally showed favorable results, including better microbiological response. A prospective observational study that compared an IV β-lactam plus IV aminoglycoside, monotherapy with inhaled colistin, and aerosolized colistin plus IV aminoglycoside found no difference in cure rates<sup><a href="#ref-58">58</a></sup>. Another study in which IV colistin was compared with IV colistin plus inhaled colistin and inhaled colistin alone also found no differences in mortality or clinical cure, and microbiological cure was better in the aerosolized group<sup><a href="#ref-59">59</a></sup>. Once susceptibility results of <i>A</i>. <i>baumannii</i> isolates become available, combination therapy may be de-escalated to monotherapy. However, tigecycline alone should be avoided, as resistance in <i>A. baumannii</i> can develop rapidly<sup><a href="#ref-60">60</a></sup>.</p><p class="" id=d6896e726>Although there have been several recent approvals of antibiotics with activity against Gram-negative pathogens (for example, delafloxacin, ceftazidime-avibactam, ceftolozane-tazobactam, and meropenem-vaborbactam), the pipeline is limited for agents effective against MDR <i>A. baumannii</i> (<a href="#T1">Table 1</a>). Cefiderocol has been shown to have potent <i>in vitro</i> activity against <i>A. baumannii</i> and exhibits high stability against carbapenemase hydrolysis<sup><a href="#ref-61">61</a></sup>.<i></i> A 52-country collection of clinical isolates obtained between 2014 and 2016 found that 330/368 (89%) of MDR <i>A</i>. <i>baumannii</i> strains had cefiderocol MICs of not more than 4 μg/mL<sup><a href="#ref-62">62</a></sup>. Another study evaluated 107 carbapenem-resistant <i>A</i>. <i>baumannii</i> isolates from 18 Greek hospitals and determined that the MIC<sub>90</sub> of cefiderocol was 0.5 mg/L, which was more active than either tigecycline or colistin<sup><a href="#ref-63">63</a></sup>. Two phase III clinical trials for cefiderocol—APEKS-NP and CREDIBLE-CR—that include VAP and HAP due to GNB are under way<sup><a href="#ref-64">64</a></sup>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. New antibiotics for multidrug-resistant Gram-negative bacteria.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d6896e787 class=n-a></a><thead><a name=d6896e789 class=n-a></a><tr><a name=d6896e791 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d6896e793 class=n-a></a>Drug</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6896e796 class=n-a></a>Class</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6896e799 class=n-a></a>Development<br class=br>stage</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6896e804 class=n-a></a>Activity</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6896e807 class=n-a></a>FDA indication</th></tr></thead><tbody><a name=d6896e812 class=n-a></a><tr><a name=d6896e814 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e816 class=n-a></a>Aztreonam/avibactam</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e819 class=n-a></a>Monobactam/β-lactamase<br class=br>inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e824 class=n-a></a>Phase II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e827 class=n-a></a>ESBL, KPC, class C β-lactamase, MBL</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e830 class=n-a></a>Not applicable</td></tr><tr><a name=d6896e834 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e836 class=n-a></a>Cefiderocol</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e839 class=n-a></a>Siderophore<br class=br>cephalosporin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e844 class=n-a></a>Phase III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e847 class=n-a></a>ESBL, CRE<br class=br>(class A, B, and D enzymes),<br class=br>carbapenem-resistant <i>Pseudomonas</i><br class=br><i>aeruginosa</i>, <i>Stenotrophomonas</i><br class=br><i>maltophilia</i>,<br class=br>and <i>Acinetobacter baumannii</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e871 class=n-a></a>Not applicable</td></tr><tr><a name=d6896e875 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e877 class=n-a></a>Ceftazidime/avibactam</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e880 class=n-a></a>Cephalosporin/β-<br class=br>lactamase inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e885 class=n-a></a>FDA-approved</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e888 class=n-a></a>ESBL, KPC, AmpC, some class D serine<br class=br>β-lactamases</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e893 class=n-a></a>HABP/VABP, cIAI,<br class=br>cUTI</td></tr><tr><a name=d6896e899 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e901 class=n-a></a>Ceftolozane/tazobactam</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e904 class=n-a></a>Cephalosporin/β-<br class=br>lactamase inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e909 class=n-a></a>FDA-approved</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e912 class=n-a></a>ESBL, MDR <i>P. aeruginosa</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e917 class=n-a></a>cUTI, cIAI</td></tr><tr><a name=d6896e921 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e923 class=n-a></a>Delafloxacin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e926 class=n-a></a>Fluoroquinolone</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e929 class=n-a></a>FDA-approved</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e932 class=n-a></a><i>Klebsiella pneumoniae</i>, including AmpC<br class=br>and class A ESBL-producers,<br class=br>ciprofloxacin-resistant <i>Escherichia coli</i><br class=br>and <i>A. baumannii</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e947 class=n-a></a>ABSSSI</td></tr><tr><a name=d6896e952 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e954 class=n-a></a>Eravacycline</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e957 class=n-a></a>Fluorocycline tetracycline</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e960 class=n-a></a>FDA-approved</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e963 class=n-a></a>ESBL, CRE, MDR <i>A. baumannii</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e968 class=n-a></a>cIAI</td></tr><tr><a name=d6896e972 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e974 class=n-a></a>Imipenem+cilastatin/<br class=br>relebactam</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e979 class=n-a></a>Carbapenem/β-lactamase<br class=br>inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e984 class=n-a></a>Phase III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e987 class=n-a></a>KPC, MDR <i>P. aeruginosa</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e992 class=n-a></a>Not applicable</td></tr><tr><a name=d6896e996 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e998 class=n-a></a>Meropenem/vaborbactam</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1001 class=n-a></a>Carbapenem/boronic acid<br class=br>inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1006 class=n-a></a>FDA-approved</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1009 class=n-a></a>CRE (class A and C enzymes)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1012 class=n-a></a>cUTI</td></tr><tr><a name=d6896e1016 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1018 class=n-a></a>Murepavadin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1021 class=n-a></a>Cyclic peptide that targets<br class=br>outer membrane</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1026 class=n-a></a>Phase III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1029 class=n-a></a>MDR <i>P. aeruginosa</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1034 class=n-a></a>Not applicable</td></tr><tr><a name=d6896e1038 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1040 class=n-a></a>Omadacycline</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1043 class=n-a></a>Aminomethylcycline</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1046 class=n-a></a>FDA-approved</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1049 class=n-a></a>ESBL, <i>A. baumannii</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1054 class=n-a></a>ABSSSI, CABP</td></tr><tr><a name=d6896e1058 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1060 class=n-a></a>Plazomicin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1063 class=n-a></a>Aminoglycoside</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1066 class=n-a></a>FDA-approved</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1069 class=n-a></a>ESBL, CRE excluding NDM producers,<br class=br><i>A. baumannii</i>, <i>P. aeruginosa</i> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d6896e1079 class=n-a></a>cUTI</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d6896e1087 class=n-a></a><p id=d6896e1089> ABSSSI, acute bacterial skin and skin structure infection; CABP, community-acquired bacterial pneumonia; cIAI, complicated intra-abdominal infection; CRE, carbapenem-resistant Enterobacteriaceae; cUTI, complicated urinary tract infection; ESBL, extended-spectrum β-lactamase; FDA, US Food and Drug Administration; HABP, hospital-acquired bacterial pneumonia; KPC, <i>Klebsiella pneumoniae</i> carbapenemase; MBL, metallo-β-lactamase; MDR, multidrug-resistant; NDM, New Delhi metallo-β-lactamase; VABP, ventilator-acquired bacterial pneumonia.</p></div></div></div><p class="" id=d6896e1099>Eravacycline was recently approved for the treatment of intra-abdominal infections and complicated urinary tract infections (cUTIs). One study showed that against carbapenem- and tigecycline-resistant <i>Acinetobacter</i> isolates, eravacycline MICs were about twofold lower versus comparator agents<sup><a href="#ref-65">65</a></sup>. However, clinical experience with eravacycline for <i>A. baumannii</i> pneumonia is limited and its role is unclear, especially given evidence of increased adverse events and mortality with tigecycline when prescribed for pneumonia<sup><a href="#ref-66">66</a></sup>.</p><p class="" id=d6896e1116>Plazomicin is a novel aminoglycoside derived from sisomicin that was modified to resist aminoglycoside-modifying enzymes and is currently approved for use in cUTIs. Significantly improved activity has been observed in OXA-producing <i>A</i>. <i>baumannii</i> compared with other aminoglycosides, and plazomicin MICs are 16 to 32 times lower<sup><a href="#ref-67">67</a></sup>. A recent clinical trial found favorable results with plazomicin in CRE VAP as well as a favorable safety profile and a low incidence of drug-related adverse events, including serum creatinine elevations<sup><a href="#ref-68">68</a></sup>. Thus, plazomicin appears promising as part of combination regimens and data on its effectiveness in HAP/VAP due to MDR <i>A. baumannii</i> are eagerly awaited.</p><p class="" id=d6896e1136>Zidebactam and WCK 5153 are two novel β-lactam antibiotics under development that display high affinity for PBP2 of GNB and overcome multiple β-lactam resistance mechanisms. When combined with cefepime or sulbactam, zidebactam and WCK 5153 demonstrated enhanced killing and full bacterial eradication after 24 hours against strains of MDR <i>A. baumannii</i><sup><a href="#ref-69">69</a></sup>. Arylomycins are a new class of lipopeptide antibiotics whose lead compound, G0775, was demonstrated to have potent activity against 16 strains of MDR <i>A. baumannii</i><sup><a href="#ref-70">70</a></sup>. The antibiotic adjuvant SPR741 sensitized <i>A. baumannii</i> to a panel of antibiotics and permitted strong potentiation of rifampin against multiple MDR <i>A. baumannii</i> isolates<sup><a href="#ref-71">71</a></sup>. Several non-antibiotic therapies against <i>A. baumannii</i> are in various stages of development (for example, bacteriophage, vaccines, and monoclonal antibodies) and have recently been reviewed<sup><a href="#ref-72">72</a></sup>. Finally, it may be possible in the future to use CRISPR-Cas systems to target plasmids that spread AMR in GNB<sup><a href="#ref-73">73</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6896e1176>Conclusions</h2><p class="" id=d6896e1179>Pneumonia due to MDR-GNB represents a serious threat to hospitalized patients. Clinicians must be knowledgeable about local resistance patterns and a patient’s risk factors for MDR-GNB to ensure appropriate empiric antimicrobial therapy. Fortunately, several new drugs that target MDR-GNB have been approved or are in late stages of development. Further pragmatic studies are needed to elucidate their place in therapy and their impact on real-world outcomes such as length of stay and mortality, especially for ICU patients with HAP/VAP.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d6896e1 class=n-a></a><h2 class=main-title id=d7114>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d6896e1186 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d7361>References</h2><div class="section ref-list"><a name=d6896e1186 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732892738"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e1193 class=n-a></a>Thorpe KE, Joski P, Johnston KJ: Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually. <i>Health Aff (Millwood).</i> 2018; <b>37</b>(4): 662–9. <a target=xrefwindow id=d6896e1201 href="http://www.ncbi.nlm.nih.gov/pubmed/29561692">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1204 href="https://doi.org/10.1377/hlthaff.2017.1153">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732892738">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726507459"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e1217 class=n-a></a>Kalil AC, Metersky ML, Klompas M, <i> et al.</i>: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis.</i> 2016; <b>63</b>(5): e61–e111. <a target=xrefwindow id=d6896e1228 href="http://www.ncbi.nlm.nih.gov/pubmed/27418577">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1231 href="https://doi.org/10.1093/cid/ciw353">Publisher Full Text </a> | <a target=xrefwindow id=d6896e1235 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4981759">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726507459">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d6896e1248 class=n-a></a>Bassetti M, Welte T, Wunderink RG: Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair? <i>Crit Care.</i> 2016; <b>20</b>: 19. <a target=xrefwindow id=d6896e1256 href="http://www.ncbi.nlm.nih.gov/pubmed/26821535">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1259 href="https://doi.org/10.1186/s13054-016-1197-5">Publisher Full Text </a> | <a target=xrefwindow id=d6896e1262 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4731981">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d6896e1271 class=n-a></a>Watkins RR, Deresinski S: Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing <i>Enterobacteriaceae</i> to slow the emergence of carbapenem-resistant <i>Enterobacteriaceae</i>. <i>Expert Rev Anti Infect Ther.</i> 2017; <b>15</b>(10): 893–5. <a target=xrefwindow id=d6896e1285 href="http://www.ncbi.nlm.nih.gov/pubmed/28914107">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1289 href="https://doi.org/10.1080/14787210.2017.1380519">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727004634"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e1298 class=n-a></a>Grundmann H, Glasner C, Albiger B, <i> et al.</i>: Occurrence of carbapenemase-producing <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. <i>Lancet Infect Dis.</i> 2017; <b>17</b>(2): 153–63. <a target=xrefwindow id=d6896e1316 href="http://www.ncbi.nlm.nih.gov/pubmed/27866944">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1319 href="https://doi.org/10.1016/S1473-3099(16)30257-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727004634">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d6896e1333 class=n-a></a>Vazquez Guillamet C, Kollef MH: <i>Acinetobacter</i> Pneumonia: Improving Outcomes With Early Identification and Appropriate Therapy. <i>Clin Infect Dis.</i> 2018; <b>67</b>(9): 1455–62. <a target=xrefwindow id=d6896e1344 href="http://www.ncbi.nlm.nih.gov/pubmed/29741597">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1347 href="https://doi.org/10.1093/cid/ciy375">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d6896e1356 class=n-a></a>Davey PG, Marwick C: Appropriate vs. inappropriate antimicrobial therapy. <i>Clin Microbiol Infect.</i> 2008; <b>14</b>(Suppl 3): 15–21. <a target=xrefwindow id=d6896e1364 href="http://www.ncbi.nlm.nih.gov/pubmed/18318875">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1367 href="https://doi.org/10.1111/j.1469-0691.2008.01959.x">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733769791"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e1376 class=n-a></a>Maruyama T, Fujisawa T, Ishida T, <i> et al.</i>: A Therapeutic Strategy for All Pneumonia Patients: A 3-Year Prospective Multicenter- Cohort Study Using Risk Factors for Multidrug Resistant Pathogens To Select Initial Empiric Therapy. <i>Clin Infect Dis.</i> 2018. <a target=xrefwindow id=d6896e1384 href="http://www.ncbi.nlm.nih.gov/pubmed/30084884">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1387 href="https://doi.org/10.1093/cid/ciy631">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733769791">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734888095"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e1400 class=n-a></a>Lat I, Daley MJ, Shewale A, <i> et al.</i>: A Multicenter, Prospective, Observational Study to Determine Predictive Factors for Multidrug-Resistant Pneumonia in Critically Ill Adults: The DEFINE Study. <i>Pharmacotherapy.</i> 2018. <a target=xrefwindow id=d6896e1408 href="http://www.ncbi.nlm.nih.gov/pubmed/30101412">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1411 href="https://doi.org/10.1002/phar.2171">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734888095">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d6896e1424 class=n-a></a>Montero M, Sala M, Riu M, <i> et al.</i>: Risk factors for multidrug-resistant <i>Pseudomonas aeruginosa</i> acquisition. Impact of antibiotic use in a double case-control study. <i>Eur J Clin Microbiol Infect Dis.</i> 2010; <b>29</b>(3): 335–9. <a target=xrefwindow id=d6896e1438 href="http://www.ncbi.nlm.nih.gov/pubmed/20033749">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1442 href="https://doi.org/10.1007/s10096-009-0850-1">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d6896e1451 class=n-a></a>Gu WJ, Wang F, Tang L, <i> et al.</i>: Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: a systematic review and meta-analysis. <i>Int J Antimicrob Agents.</i> 2014; <b>44</b>(6): 477–85. <a target=xrefwindow id=d6896e1462 href="http://www.ncbi.nlm.nih.gov/pubmed/25199968">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1465 href="https://doi.org/10.1016/j.ijantimicag.2014.07.004">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733715313"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e1475 class=n-a></a>Sader HS, Castanheira M, Mendes RE, <i> et al.</i>: Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17). <i>J Antimicrob Chemother.</i> 2018; <b>73</b>(11): 3053–9. <a target=xrefwindow id=d6896e1486 href="http://www.ncbi.nlm.nih.gov/pubmed/30060117">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1489 href="https://doi.org/10.1093/jac/dky279">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733715313">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d6896e1502 class=n-a></a>Jacoby GA: AmpC beta-lactamases. <i>Clin Microbiol Rev.</i> 2009; <b>22</b>(1): 161–82. <a target=xrefwindow id=d6896e1510 href="http://www.ncbi.nlm.nih.gov/pubmed/19136439">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1513 href="https://doi.org/10.1128/CMR.00036-08">Publisher Full Text </a> | <a target=xrefwindow id=d6896e1516 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2620637">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d6896e1525 class=n-a></a>Hauck C, Cober E, Richter SS, <i> et al.</i>: Spectrum of excess mortality due to carbapenem-resistant <i>Klebsiella pneumoniae</i> infections. <i>Clin Microbiol Infect.</i> 2016; <b>22</b>(6): 513–9. <a target=xrefwindow id=d6896e1539 href="http://www.ncbi.nlm.nih.gov/pubmed/26850824">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1543 href="https://doi.org/10.1016/j.cmi.2016.01.023">Publisher Full Text </a> | <a target=xrefwindow id=d6896e1546 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4930369">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d6896e1555 class=n-a></a>Safdar N, Maki DG: The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant <i>Staphylococcus aureus</i>, <i>enterococcus</i>, gram-negative bacilli, <i>Clostridium difficile</i>, and <i>Candida</i>. <i>Ann Intern Med.</i> 2002; <b>136</b>(11): 834–44. <a target=xrefwindow id=d6896e1576 href="http://www.ncbi.nlm.nih.gov/pubmed/12044132">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1579 href="https://doi.org/10.7326/0003-4819-136-11-200206040-00013">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726882482"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e1588 class=n-a></a>Bassetti M, Carnelutti A, Peghin M: Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections. <i>Expert Rev Anti Infect Ther.</i> 2017; <b>15</b>(1): 55–65. <a target=xrefwindow id=d6896e1596 href="http://www.ncbi.nlm.nih.gov/pubmed/27766913">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1599 href="https://doi.org/10.1080/14787210.2017.1251840">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726882482">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732675348"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e1612 class=n-a></a>Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, <i> et al.</i>: Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing <i>Enterobacteriaceae</i>. <i>Clin Microbiol Rev.</i> 2018; <b>31</b>(2): pii: e00079-17. <a target=xrefwindow id=d6896e1626 href="http://www.ncbi.nlm.nih.gov/pubmed/29444952">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1630 href="https://doi.org/10.1128/CMR.00079-17">Publisher Full Text </a> | <a target=xrefwindow id=d6896e1633 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5967687">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732675348">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734001238"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e1647 class=n-a></a>Harris PNA, Tambyah PA, Lye DC, <i> et al.</i>: Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial <i>JAMA.</i> 2018; <b>320</b>(10): 984–994. <a target=xrefwindow id=d6896e1665 href="http://www.ncbi.nlm.nih.gov/pubmed/30208454">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1668 href="https://doi.org/10.1001/jama.2018.12163">Publisher Full Text </a> | <a target=xrefwindow id=d6896e1671 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6143100">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734001238">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d6896e1684 class=n-a></a>Tamma PD, Villegas MV: Use of β-Lactam/β-Lactamase Inhibitors for Extended-Spectrum-β-Lactamase Infections: Defining the Right Patient Population. <i>Antimicrob Agents Chemother.</i> 2017; <b>61</b>(8): pii: e01094-17. <a target=xrefwindow id=d6896e1692 href="http://www.ncbi.nlm.nih.gov/pubmed/28584153">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1695 href="https://doi.org/10.1128/AAC.01094-17">Publisher Full Text </a> | <a target=xrefwindow id=d6896e1698 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5527567">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d6896e1707 class=n-a></a>Zanetti G, Bally F, Greub G, <i> et al.</i>: Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. <i>Antimicrob Agents Chemother.</i> 2003; <b>47</b>(11): 3442–7. <a target=xrefwindow id=d6896e1718 href="http://www.ncbi.nlm.nih.gov/pubmed/14576100">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1721 href="https://doi.org/10.1128/AAC.47.11.3442-3447.2003">Publisher Full Text </a> | <a target=xrefwindow id=d6896e1725 href="http://www.ncbi.nlm.nih.gov/pmc/articles/253800">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727443005"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e1734 class=n-a></a>Cheng L, Nelson BC, Mehta M, <i> et al.</i>: Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment of Bloodstream Infections Due to AmpC β-Lactamase-Producing <i>Enterobacteriaceae</i>. <i>Antimicrob Agents Chemother.</i> 2017; <b>61</b>(1): pii: e00276-17. <a target=xrefwindow id=d6896e1748 href="http://www.ncbi.nlm.nih.gov/pubmed/28320724">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1752 href="https://doi.org/10.1128/AAC.00276-17">Publisher Full Text </a> | <a target=xrefwindow id=d6896e1755 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5444164">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727443005">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d6896e1768 class=n-a></a>Tamma PD, Girdwood SC, Gopaul R, <i> et al.</i>: The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae. <i>Clin Infect Dis.</i> 2013; <b>57</b>(6): 781–8. <a target=xrefwindow id=d6896e1779 href="http://www.ncbi.nlm.nih.gov/pubmed/23759352">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1782 href="https://doi.org/10.1093/cid/cit395">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d6896e1791 class=n-a></a>van Duin D, Doi Y: The global epidemiology of carbapenemase-producing Enterobacteriaceae. <i>Virulence.</i> 2017; <b>8</b>(4): 460–9. <a target=xrefwindow id=d6896e1799 href="http://www.ncbi.nlm.nih.gov/pubmed/27593176">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1802 href="https://doi.org/10.1080/21505594.2016.1222343">Publisher Full Text </a> | <a target=xrefwindow id=d6896e1805 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5477705">Free Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d6896e1815 class=n-a></a>van Duin D, Kaye KS, Neuner EA, <i> et al.</i>: Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. <i>Diagn Microbiol Infect Dis.</i> 2013; <b>75</b>(2): 115–20. <a target=xrefwindow id=d6896e1826 href="http://www.ncbi.nlm.nih.gov/pubmed/23290507">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1829 href="https://doi.org/10.1016/j.diagmicrobio.2012.11.009">Publisher Full Text </a> | <a target=xrefwindow id=d6896e1833 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3947910">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d6896e1842 class=n-a></a>van Duin D, Bonomo RA: Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. <i>Clin Infect Dis.</i> 2016; <b>63</b>(2): 234–41. <a target=xrefwindow id=d6896e1850 href="http://www.ncbi.nlm.nih.gov/pubmed/27098166">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1853 href="https://doi.org/10.1093/cid/ciw243">Publisher Full Text </a> | <a target=xrefwindow id=d6896e1856 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4928383">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d6896e1865 class=n-a></a>Kaye KS, Vazquez J, Mathers A, <i> et al.</i>: Clinical Outcomes of Serious Infections due to Carbapenem-Resistant Enterobacteriaceae (CRE) in TANGO II, a Phase 3, Randomized, Multi-National, Open-Label Trial of Meropenem-Vaborbactam (M-V) Vs. Best Available Therapy (BAT). <i>Open Forum Infect Dis.</i> 2017; <b>4</b>(suppl_1): S534–S535. <a target=xrefwindow id=d6896e1876 href="https://doi.org/10.1093/ofid/ofx163.1392">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d6896e1885 class=n-a></a>Karaiskos I, Souli M, Giamarellou H: Plazomicin: an investigational therapy for the treatment of urinary tract infections. <i>Expert Opin Investig Drugs.</i> 2015; <b>24</b>(11): 1501–11. <a target=xrefwindow id=d6896e1893 href="http://www.ncbi.nlm.nih.gov/pubmed/26419762">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1896 href="https://doi.org/10.1517/13543784.2015.1095180">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732040662"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e1905 class=n-a></a>Zhang Y, Kashikar A, Bush K: <i>In vitro</i> activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE). <i>J Antimicrob Chemother.</i> 2017; <b>72</b>(10): 2792–5. <a target=xrefwindow id=d6896e1916 href="http://www.ncbi.nlm.nih.gov/pubmed/29091224">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1919 href="https://doi.org/10.1093/jac/dkx261">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732040662">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732323316"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e1932 class=n-a></a>Zhanel GG, Lawrence CK, Adam H, <i> et al.</i>: Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. <i>Drugs.</i> 2018; <b>78</b>(1): 65–98. <a target=xrefwindow id=d6896e1943 href="http://www.ncbi.nlm.nih.gov/pubmed/29230684">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1946 href="https://doi.org/10.1007/s40265-017-0851-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732323316">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d6896e1960 class=n-a></a>Thakare R, Dasgupta A, Chopra S: Eravacycline for the treatment of patients with bacterial infections. <i>Drugs Today (Barc).</i> 2018; <b>54</b>(4): 245–54. <a target=xrefwindow id=d6896e1968 href="http://www.ncbi.nlm.nih.gov/pubmed/29869646">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1971 href="https://doi.org/10.1358/dot.2018.54.4.2800623">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d6896e1980 class=n-a></a>van Duin D, Lok JJ, Earley M, <i> et al.</i>: Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. <i>Clin Infect Dis.</i> 2018; <b>66</b>(2): 163–71. <a target=xrefwindow id=d6896e1991 href="http://www.ncbi.nlm.nih.gov/pubmed/29020404">PubMed Abstract </a> | <a target=xrefwindow id=d6896e1994 href="https://doi.org/10.1093/cid/cix783">Publisher Full Text </a> | <a target=xrefwindow id=d6896e1998 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5850032">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d6896e2007 class=n-a></a>Achaogen: Achaogen Announces Positive Results in Phase 3 cUTI and CRE Clinical Trials of Plazomicin. Press release. 2016. <a target=xrefwindow id=d6896e2009 href="http://investors.achaogen.com/static-files/b87e0dd5-99d6-4aa5-b4dc-2db9891f289b">Reference Source</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732327195"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e2018 class=n-a></a>Torres A, Zhong N, Pachl J, <i> et al.</i>: Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. <i>Lancet Infect Dis.</i> 2018; <b>18</b>(3): 285–95. <a target=xrefwindow id=d6896e2029 href="http://www.ncbi.nlm.nih.gov/pubmed/29254862">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2032 href="https://doi.org/10.1016/S1473-3099(17)30747-8">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732327195">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d6896e2045 class=n-a></a>Mehta M, Uhlemann AC: Beware of broad-spectrum generalizations: ceftazidime-avibactam compared to meropenem for the treatment of gram-negative pneumonia. <i>J Emerg Crit Care Med.</i> 2018; <b>2</b>: pii: 45. <a target=xrefwindow id=d6896e2053 href="http://www.ncbi.nlm.nih.gov/pubmed/30123873">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2056 href="https://doi.org/10.21037/jeccm.2018.05.02">Publisher Full Text </a> | <a target=xrefwindow id=d6896e2059 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6097712">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733635252"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e2068 class=n-a></a>Bassetti M, Vena A, Croxatto A, <i> et al.</i>: How to manage <i>Pseudomonas aeruginosa</i> infections. <i>Drugs Context.</i> 2018; <b>7</b>: 212527. <a target=xrefwindow id=d6896e2082 href="http://www.ncbi.nlm.nih.gov/pubmed/29872449">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2086 href="https://doi.org/10.7573/dic.212527">Publisher Full Text </a> | <a target=xrefwindow id=d6896e2089 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5978525">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733635252">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d6896e2103 class=n-a></a>Micek ST, Wunderink RG, Kollef MH, <i> et al.</i>: An international multicenter retrospective study of <i>Pseudomonas aeruginosa</i> nosocomial pneumonia: impact of multidrug resistance. <i>Crit Care.</i> 2015; <b>19</b>(1): 219. <a target=xrefwindow id=d6896e2117 href="http://www.ncbi.nlm.nih.gov/pubmed/25944081">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2121 href="https://doi.org/10.1186/s13054-015-0926-5">Publisher Full Text </a> | <a target=xrefwindow id=d6896e2124 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4446947">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d6896e2133 class=n-a></a>Bauer KA, West JE, O'Brien JM, <i> et al.</i>: Extended-infusion cefepime reduces mortality in patients with <i>Pseudomonas aeruginosa</i> infections. <i>Antimicrob Agents Chemother.</i> 2013; <b>57</b>(7): 2907–12. <a target=xrefwindow id=d6896e2147 href="http://www.ncbi.nlm.nih.gov/pubmed/23571547">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2151 href="https://doi.org/10.1128/AAC.02365-12">Publisher Full Text </a> | <a target=xrefwindow id=d6896e2154 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3697364">Free Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d6896e2163 class=n-a></a>Zhanel GG, Chung P, Adam H, <i> et al.</i>: Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. <i>Drugs.</i> 2014; <b>74</b>(1): 31–51. <a target=xrefwindow id=d6896e2174 href="http://www.ncbi.nlm.nih.gov/pubmed/24352909">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2177 href="https://doi.org/10.1007/s40265-013-0168-2">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d6896e2186 class=n-a></a>Xiao AJ, Miller BW, Huntington JA, <i> et al.</i>: Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. <i>J Clin Pharmacol.</i> 2016; <b>56</b>(1): 56–66. <a target=xrefwindow id=d6896e2197 href="http://www.ncbi.nlm.nih.gov/pubmed/26096377">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2200 href="https://doi.org/10.1002/jcph.566">Publisher Full Text </a> | <a target=xrefwindow id=d6896e2204 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5049594">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733035839"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e2213 class=n-a></a>Katchanov J, Asar L, Klupp EM, <i> et al.</i>: Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations. <i>PLoS One.</i> 2018; <b>13</b>(4): e0195757. <a target=xrefwindow id=d6896e2224 href="http://www.ncbi.nlm.nih.gov/pubmed/29649276">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2227 href="https://doi.org/10.1371/journal.pone.0195757">Publisher Full Text </a> | <a target=xrefwindow id=d6896e2231 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5896976">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733035839">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733464902"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e2244 class=n-a></a>Stone GG, Newell P, Gasink LB, <i> et al.</i>: Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and <i>Pseudomonas aeruginosa</i>: pooled data from the ceftazidime/avibactam Phase III clinical trial programme. <i>J Antimicrob Chemother.</i> 2018; <b>73</b>(9): 2519–23. <a target=xrefwindow id=d6896e2258 href="http://www.ncbi.nlm.nih.gov/pubmed/29912399">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2262 href="https://doi.org/10.1093/jac/dky204">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733464902">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733712838"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e2276 class=n-a></a>Rodríguez-Núñez O, Ripa M, Morata L, <i> et al.</i>: Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant <i>Pseudomonas aeruginosa</i>. <i>J Glob Antimicrob Resist.</i> 2018; <b>15</b>: 136–9. <a target=xrefwindow id=d6896e2290 href="http://www.ncbi.nlm.nih.gov/pubmed/30036695">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2294 href="https://doi.org/10.1016/j.jgar.2018.07.010">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733712838">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d6896e2307 class=n-a></a>Möllmann U, Heinisch L, Bauernfeind A, <i> et al.</i>: Siderophores as drug delivery agents: application of the "Trojan Horse" strategy. <i>Biometals.</i> 2009; <b>22</b>(4): 615–24. <a target=xrefwindow id=d6896e2318 href="http://www.ncbi.nlm.nih.gov/pubmed/19214755">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2321 href="https://doi.org/10.1007/s10534-009-9219-2">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727846566"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e2330 class=n-a></a>Dobias J, Dénervaud-Tendon V, Poirel L, <i> et al.</i>: Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. <i>Eur J Clin Microbiol Infect Dis.</i> 2017; <b>36</b>(12): 2319–27. <a target=xrefwindow id=d6896e2341 href="http://www.ncbi.nlm.nih.gov/pubmed/28748397">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2344 href="https://doi.org/10.1007/s10096-017-3063-z">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727846566">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d6896e2357 class=n-a></a>Ito A, Kohira N, Bouchillon SK, <i> et al.</i>: <i>In vitro</i> antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. <i>J Antimicrob Chemother.</i> 2016; <b>71</b>(3): 670–7. <a target=xrefwindow id=d6896e2371 href="http://www.ncbi.nlm.nih.gov/pubmed/26645269">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2375 href="https://doi.org/10.1093/jac/dkv402">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d6896e2384 class=n-a></a>Nguyen L, Garcia J, Gruenberg K, <i> et al.</i>: Multidrug-Resistant <i>Pseudomonas</i> Infections: Hard to Treat, But Hope on the Horizon? <i>Curr Infect Dis Rep.</i> 2018; <b>20</b>(8): 23. <a target=xrefwindow id=d6896e2398 href="http://www.ncbi.nlm.nih.gov/pubmed/29876674">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2402 href="https://doi.org/10.1007/s11908-018-0629-6">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733754733"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e2411 class=n-a></a>Karlowsky JA, Lob SH, Young K, <i> et al.</i>: Activity of imipenem/relebactam against <i>Pseudomonas aeruginosa</i> with antimicrobial-resistant phenotypes from seven global regions: SMART 2015–2016. <i>J Glob Antimicrob Resist.</i> 2018; <b>15</b>: 140–7. <a target=xrefwindow id=d6896e2425 href="http://www.ncbi.nlm.nih.gov/pubmed/30071354">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2429 href="https://doi.org/10.1016/j.jgar.2018.07.012">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733754733">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732692561"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e2443 class=n-a></a>Martin-Loeches I, Dale GE, Torres A: Murepavadin: a new antibiotic class in the pipeline. <i>Expert Rev Anti Infect Ther.</i> 2018; <b>16</b>(4): 259–68. <a target=xrefwindow id=d6896e2451 href="http://www.ncbi.nlm.nih.gov/pubmed/29451043">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2454 href="https://doi.org/10.1080/14787210.2018.1441024">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732692561">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733450378"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e2467 class=n-a></a>Sader HS, Flamm RK, Dale GE, <i> et al.</i>: Murepavadin activity tested against contemporary (2016–17) clinical isolates of XDR <i>Pseudomonas aeruginosa</i>. <i>J Antimicrob Chemother.</i> 2018; <b>73</b>(9): 2400–4. <a target=xrefwindow id=d6896e2481 href="http://www.ncbi.nlm.nih.gov/pubmed/29901750">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2485 href="https://doi.org/10.1093/jac/dky227">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733450378">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733176910"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e2498 class=n-a></a>Serota DP, Sexton ME, Kraft CS, <i> et al.</i>: Severe Community-Acquired Pneumonia due to <i>Acinetobacter baumannii</i> in North America: Case Report and Review of the Literature. <i>Open Forum Infect Dis.</i> 2018; <b>5</b>(3): ofy044. <a target=xrefwindow id=d6896e2512 href="http://www.ncbi.nlm.nih.gov/pubmed/29564365">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2516 href="https://doi.org/10.1093/ofid/ofy044">Publisher Full Text </a> | <a target=xrefwindow id=d6896e2519 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5846288">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733176910">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733135641"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e2532 class=n-a></a>Cohen B, Liu J, Larson E: Changes in the incidence and antimicrobial susceptibility of healthcare-associated infections in a New York hospital system, 2006–2012. <i>J Prev Med Hyg.</i> 2017; <b>58</b>(4): E294–E301. <a target=xrefwindow id=d6896e2540 href="http://www.ncbi.nlm.nih.gov/pubmed/29707660">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2543 href="https://doi.org/10.15167/2421-4248/jpmh2017.58.4.774">Publisher Full Text </a> | <a target=xrefwindow id=d6896e2546 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5912789">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733135641">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d6896e2559 class=n-a></a>Guillamet CV, Vazquez R, Noe J, <i> et al.</i>: A cohort study of bacteremic pneumonia: The importance of antibiotic resistance and appropriate initial therapy? <i>Medicine (Baltimore).</i> 2016; <b>95</b>(35): e4708. <a target=xrefwindow id=d6896e2570 href="http://www.ncbi.nlm.nih.gov/pubmed/27583907">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2573 href="https://doi.org/10.1097/MD.0000000000004708">Publisher Full Text </a> | <a target=xrefwindow id=d6896e2577 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5008591">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733847926"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e2586 class=n-a></a>Bickenbach J, Schöneis D, Marx G, <i> et al.</i>: Impact of multidrug-resistant bacteria on outcome in patients with prolonged weaning. <i>BMC Pulm Med.</i> 2018; <b>18</b>(1): 141. <a target=xrefwindow id=d6896e2597 href="http://www.ncbi.nlm.nih.gov/pubmed/30126392">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2600 href="https://doi.org/10.1186/s12890-018-0708-3">Publisher Full Text </a> | <a target=xrefwindow id=d6896e2604 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6102812">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733847926">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d6896e2618 class=n-a></a>Zilberberg MD, Nathanson BH, Sulham K, <i> et al.</i>: Multidrug resistance, inappropriate empiric therapy, and hospital mortality in <i>Acinetobacter baumannii</i> pneumonia and sepsis. <i>Crit Care.</i> 2016; <b>20</b>(1): 221. <a target=xrefwindow id=d6896e2632 href="http://www.ncbi.nlm.nih.gov/pubmed/27417949">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2636 href="https://doi.org/10.1186/s13054-016-1392-4">Publisher Full Text </a> | <a target=xrefwindow id=d6896e2639 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4946176">Free Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d6896e2648 class=n-a></a>Garnacho-Montero J, Dimopoulos G, Poulakou G, <i> et al.</i>: Task force on management and prevention of <i>Acinetobacter baumannii</i> infections in the ICU. <i>Intensive Care Med.</i> 2015; <b>41</b>(12): 2057–75. <a target=xrefwindow id=d6896e2662 href="http://www.ncbi.nlm.nih.gov/pubmed/26438224">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2666 href="https://doi.org/10.1007/s00134-015-4079-4">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d6896e2675 class=n-a></a>Khawcharoenporn T, Pruetpongpun N, Tiamsak P, <i> et al.</i>: Colistin-based treatment for extensively drug-resistant <i>Acinetobacter baumannii</i> pneumonia. <i>Int J Antimicrob Agents.</i> 2014; <b>43</b>(4): 378–82. <a target=xrefwindow id=d6896e2689 href="http://www.ncbi.nlm.nih.gov/pubmed/24613422">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2693 href="https://doi.org/10.1016/j.ijantimicag.2014.01.016">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734888228"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e2702 class=n-a></a>Alp E, Eren E, Elay G, <i> et al.</i>: Efficacy of loading dose of colistin in <i>Acinetobacter baumannii</i> ventilator-associated pneumonia. <i>Infez Med.</i> 2017; <b>25</b>(4): 311–319. <a target=xrefwindow id=d6896e2716 href="http://www.ncbi.nlm.nih.gov/pubmed/29286009">PubMed Abstract </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734888228">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d6896e2729 class=n-a></a>Lu Q, Luo R, Bodin L, <i> et al.</i>: Efficacy of High-dose Nebulized Colistin in Ventilator-associated Pneumonia Caused by Multidrug-resistant <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i>. <i>Anesthesiology.</i> 2012; <b>117</b>(6): 1335–47. <a target=xrefwindow id=d6896e2747 href="http://www.ncbi.nlm.nih.gov/pubmed/23132092">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2750 href="https://doi.org/10.1097/ALN.0b013e31827515de">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d6896e2759 class=n-a></a>Pérez-Pedrero MJ, Sánchez-Casado M, Rodríguez-Villar S: Utilización de la colistina nebulizada en la colonización e infección respiratoria por Acinetobacter <i>baumannii</i> en pacientes críticos. <i>Medicina Intensiva.</i> 2011; <b>35</b>(4): 226–31. <a target=xrefwindow id=d6896e2770 href="http://scielo.isciii.es/pdf/medinte/v35n4/original3.pdf">Reference Source</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d6896e2780 class=n-a></a>Li X, Liu L, Ji J, <i> et al.</i>: Tigecycline resistance in <i>Acinetobacter baumannii</i> mediated by frameshift mutation in plsC, encoding 1-acyl-sn-glycerol-3-phosphate acyltransferase. <i>Eur J Clin Microbiol Infect Dis.</i> 2015; <b>34</b>(3): 625–31. <a target=xrefwindow id=d6896e2794 href="http://www.ncbi.nlm.nih.gov/pubmed/25407371">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2798 href="https://doi.org/10.1007/s10096-014-2272-y">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731116093"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e2807 class=n-a></a>Wright H, Bonomo RA, Paterson DL: New agents for the treatment of infections with Gram-negative bacteria: Restoring the miracle or false dawn? <i>Clin Microbiol Infect.</i> 2017; <b>23</b>(10): 704–712. <a target=xrefwindow id=d6896e2815 href="http://www.ncbi.nlm.nih.gov/pubmed/28893690">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2818 href="https://doi.org/10.1016/j.cmi.2017.09.001">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731116093">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732142063"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e2831 class=n-a></a>Hackel MA, Tsuji M, Yamano Y, <i> et al.</i>: <i>In Vitro</i> Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016. <i>Antimicrob Agents Chemother.</i> 2018; <b>62</b>(2): pii: e01968-17. <a target=xrefwindow id=d6896e2845 href="http://www.ncbi.nlm.nih.gov/pubmed/29158270">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2849 href="https://doi.org/10.1128/AAC.01968-17">Publisher Full Text </a> | <a target=xrefwindow id=d6896e2852 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5786755">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732142063">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727471842"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e2865 class=n-a></a>Falagas ME, Skalidis T, Vardakas KZ, <i> et al.</i>: Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. <i>J Antimicrob Chemother.</i> 2017; <b>72</b>(6): 1704–1708. <a target=xrefwindow id=d6896e2876 href="http://www.ncbi.nlm.nih.gov/pubmed/28369471">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2879 href="https://doi.org/10.1093/jac/dkx049">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727471842">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d6896e2892 class=n-a></a>Bassetti M, Vena A, Castaldo N, <i> et al.</i>: New antibiotics for ventilator-associated pneumonia. <i>Curr Opin Infect Dis.</i> 2018; <b>31</b>(2): 177–186. <a target=xrefwindow id=d6896e2903 href="http://www.ncbi.nlm.nih.gov/pubmed/29337703">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2906 href="https://doi.org/10.1097/QCO.0000000000000438">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d6896e2915 class=n-a></a>Livermore DM, Mushtaq S, Warner M, <i> et al.</i>: <i>In Vitro</i> Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and <i>Acinetobacter baumannii</i>. <i>Antimicrob Agents Chemother.</i> 2016; <b>60</b>(6): 3840–4. <a target=xrefwindow id=d6896e2933 href="http://www.ncbi.nlm.nih.gov/pubmed/27044556">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2936 href="https://doi.org/10.1128/AAC.00436-16">Publisher Full Text </a> | <a target=xrefwindow id=d6896e2939 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4879382">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d6896e2949 class=n-a></a>Shen F, Han Q, Di Xie, <i> et al.</i>: Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs. <i>Int J Infect Dis.</i> 2015; <b>39</b>: 25–33. <a target=xrefwindow id=d6896e2960 href="http://www.ncbi.nlm.nih.gov/pubmed/26283551">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2963 href="https://doi.org/10.1016/j.ijid.2015.08.009">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d6896e2972 class=n-a></a>García-Salguero C, Rodríguez-Avial I, Picazo JJ, <i> et al.</i>: Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant <i>Acinetobacter baumannii</i>? <i>Antimicrob Agents Chemother.</i> 2015; <b>59</b>(10): 5959–66. <a target=xrefwindow id=d6896e2986 href="http://www.ncbi.nlm.nih.gov/pubmed/26169398">PubMed Abstract </a> | <a target=xrefwindow id=d6896e2990 href="https://doi.org/10.1128/AAC.00873-15">Publisher Full Text </a> | <a target=xrefwindow id=d6896e2993 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4576036">Free Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d6896e3002 class=n-a></a>Connolly LE, Jubb AM, Keeffe BO, <i> et al.</i>: Plazomicin is associated with improved survival and safety compared to colistin in serious carbapenem-resistant Enterobacteriaceae (CRE) infections: results of the CARE study. Presented at: ASM Microbe; 2017; New Orleans, LA. <a target=xrefwindow id=d6896e3007 href="https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=52433">Reference Source</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/729805200"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e3016 class=n-a></a>Moya B, Barcelo IM, Bhagwat S, <i> et al.</i>: Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against <i>Acinetobacter baumannii</i>, Including Carbapenemase-Producing Clinical Isolates. <i>Antimicrob Agents Chemother.</i> 2017; <b>61</b>(11): pii: e01238-17. <a target=xrefwindow id=d6896e3030 href="http://www.ncbi.nlm.nih.gov/pubmed/28848013">PubMed Abstract </a> | <a target=xrefwindow id=d6896e3034 href="https://doi.org/10.1128/AAC.01238-17">Publisher Full Text </a> | <a target=xrefwindow id=d6896e3037 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5655067">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/729805200">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734001418"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e3050 class=n-a></a>Smith PA, Koehler MFT, Girgis HS, <i> et al.</i>: Optimized arylomycins are a new class of Gram-negative antibiotics. <i>Nature.</i> 2018; <b>561</b>(7722): 189–94. <a target=xrefwindow id=d6896e3061 href="http://www.ncbi.nlm.nih.gov/pubmed/30209367">PubMed Abstract </a> | <a target=xrefwindow id=d6896e3064 href="https://doi.org/10.1038/s41586-018-0483-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734001418">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732850977"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6896e3077 class=n-a></a>Domalaon R, Idowu T, Zhanel GG, <i> et al.</i>: Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens? <i>Clin Microbiol Rev.</i> 2018; <b>31</b>(2): pii: e00077-17. <a target=xrefwindow id=d6896e3088 href="http://www.ncbi.nlm.nih.gov/pubmed/29540434">PubMed Abstract </a> | <a target=xrefwindow id=d6896e3091 href="https://doi.org/10.1128/CMR.00077-17">Publisher Full Text </a> | <a target=xrefwindow id=d6896e3095 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5967690">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732850977">F1000 Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d6896e3109 class=n-a></a>Watkins RR: A formidable foe: carbapenem-resistant <i>Acinetobacter baumannii</i> and emerging nonantibiotic therapies. <i>Expert Rev Anti Infect Ther.</i> 2018; <b>16</b>(8): 591–3. <a target=xrefwindow id=d6896e3120 href="http://www.ncbi.nlm.nih.gov/pubmed/30024320">PubMed Abstract </a> | <a target=xrefwindow id=d6896e3123 href="https://doi.org/10.1080/14787210.2018.1503054">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d6896e3132 class=n-a></a>Bober JR, Beisel CL, Nair NU: Synthetic Biology Approaches to Engineer Probiotics and Members of the Human Microbiota for Biomedical Applications. <i>Annu Rev Biomed Eng.</i> 2018; <b>20</b>: 277–300. <a target=xrefwindow id=d6896e3140 href="http://www.ncbi.nlm.nih.gov/pubmed/29528686">PubMed Abstract </a> | <a target=xrefwindow id=d6896e3143 href="https://doi.org/10.1146/annurev-bioeng-062117-121019">Publisher Full Text </a> | <a target=xrefwindow id=d6896e3146 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6100750">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 2 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 2</span> <span class=details>PUBLISHED 30 Jan 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-121&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-121&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Division of Infectious Diseases, Cleveland Clinic Akron General, Akron, OH, 44302, USA<br/> <sup>2</sup> Department of Medicine, Northeast Ohio Medical University, Rootstown, OH, 44272, USA<br/> <sup>3</sup> Department of Medicine, University of North Carolina, Chapel Hill, NC, 27514, USA<br/> <p> <div class=margin-bottom> Richard R. Watkins <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> David Van Duin <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (2)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-121/v2" title="Open version 2 of this article." class="" gahelper=2>version 2</a> <span class="article-pubinfo-mobile versions-section"> <div title="#springMessage("NewVersionReasonType.REVISED.tooltip")" class="version-info-box revised ">Revised</div> </span> </div> <div> Published: 06 Feb 2019, 8:121 </div> <div class=margin-bottom><a href="https://doi.org/10.12688/f1000research.16517.2">https://doi.org/10.12688/f1000research.16517.2</a></div> <div> <a href="https://f1000research.com/articles/8-121/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 30 Jan 2019, 8:121 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.16517.1">https://doi.org/10.12688/f1000research.16517.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Watkins RR and Van Duin D. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=19889 data-id=16517 data-downloads="" data-views="" data-scholar="10.12688/f1000research.16517.2" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-121/v2/pdf?article_uuid=7b526853-586f-45ec-81eb-ffa3dcf7697c" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.16517.2"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Watkins RR and Van Duin D. Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria [version 2; peer review: 2 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):121 (<a href="https://doi.org/10.12688/f1000research.16517.2" target=_blank>https://doi.org/10.12688/f1000research.16517.2</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=16517 id=mobile-track-article-signin-16517 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/16517?target=/articles/8-121"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=19889 /> <input name=articleId type=hidden value=16517 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Frank Schweizer</strong>, Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Canada </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Dean Winslow</strong>, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 2 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 2</span> <span class=details>PUBLISHED 30 Jan 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-121&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-121&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=44948-43432></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=44949-43431></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--empty c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v2_version href="https://f1000research.com/articles/8-121/v2">Version 2</a><br/> <span class=p-article__color--dark> <span class=c-report-timeline__update-type data-test-id=sidebar_timeline_v2_update-type>(revision)<br/></span> <span data-test-id=sidebar_timeline_v2_date class=c-report-timeline__date>06 Feb 19</span> </span> </th> <td class="c-report-timeline__report--empty c-report-timeline__cell c-report-timeline__report--has-prev "></td> <td class="c-report-timeline__report--empty c-report-timeline__cell c-report-timeline__report--has-prev "></td> </tr> <tr class="c-report-timeline__row "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-121/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>30 Jan 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Frank Schweizer</strong>, Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Canada </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Dean Winslow</strong>, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-121&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-121/v2/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Current trends in the treatment of pneumonia...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-121/v2" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-121/v2&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-121/v2" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Watkins RR and Van Duin D');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-121/v2/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-121",
            templates : {
                twitter : "Current trends in the treatment of pneumonia due to multidrug-resistant.... Watkins RR and Van Duin D, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-121/v2"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/16517/19889")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "19889");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "43431": 0,
                           "43432": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "c6ece3c0-2158-4b02-8372-e184fe8fa82a";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-121.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-121.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-121.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-121.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-121.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>